

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

85552

CORRESPONDENCE

NDA 85-552

JUL 25 1977

Chelson Laboratories, Inc.
Attention: Mr. Max Getrajdman
428 Doughty Blvd.
Inwood, NY 11696

Gentlemen:

Reference is made to your abbreviated new drug application submitted pursuant to section 505(b) of the Federal Food, Drug, and Cosmetic Act for Probenecid 500 mg. with Colchicine 0.5 mg. Tablets.

Reference is also made to your communication dated July 1, 1977 relating to control information.

We have completed the review of this abbreviated new drug application and have the following comments:

Samples and methodology have been submitted to our laboratory for evaluation. We will correspond with you on completion of their studies.

The material submitted is being retained as part of your application.

cc: NYK-DO

HFD-614
JMayer/CChang/7-21-77
R/D init. JMayer/MSaife/7/21/77
ca/7/21/77
ack

JMayer 7/22/77

[Handwritten signature]
15/

7/25/77

[Handwritten signature]
Harold Saife, R.D.
Director
Division of Genetic Drug Monographs
Office of Drug Monographs
Bureau of Drugs

DEC 29 1976

NDA 85-552

Chelsea Laboratories, Inc.
Attention: Nat Getrajdman
428 Doughty Blvd.
Inwood, NY 11696

Gentlemen:

We acknowledge the receipt of your abbreviated new drug application submitted pursuant to Section 305(b) of the Federal Food, Drug, and Cosmetic Act for the following:

NAME OF DRUG: Probenecid 500 mg. with Colchicine 0.5 mg. Tablets

DATE OF APPLICATION: December 14, 1976

DATE OF RECEIPT: December 17, 1976

We will correspond with you further after we have had the opportunity to review the application.

Please identify any communications concerning this application with the NDA number shown above.

NYC-DO DUP HFD-614, NFB-616
JLMeyer/cjb/12-28-76

ack

ack 12/29/76

Sincerely yours,

for *ISI* *12/29/76*
Nervin Sethi, M.D.
Director
Division of Generic Drug Monographs
Office of Drug Monographs
Bureau of Drugs



DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
ROCKVILLE, MARYLAND 20852

NDA 85-552

FEB 9 1977

Chelsea Laboratories, Inc.
Attention: Nat Getrajdman
428 Doughty Blvd.
Inwood, NY 11696

Gentlemen:

Reference is made to your abbreviated new drug application dated December 14, 1976, submitted pursuant to Section 505(b) of the Federal Food, Drug, and Cosmetic Act for Probenecid 500 mg. with Colchicine 0.5 mg. Tablets.

We have completed the review of this abbreviated new drug application. However, before we are able to reach a final conclusion, the following additional information is necessary:

1. Include information on containers and closures.
2. Noting the "extremely poisonous" and light sensitive nature of colchicine, include an expanded manufacturing outline clarifying any special procedures/precautions observed in the operations.
3. To expedite the processing of this application, we are requesting samples of the final dosage form together with your analytical results for their testing.
4. We are unable to reach any conclusion on expiration dating. It is recommended that stability data be submitted when it becomes available.

Please let us have your response promptly.

Sincerely yours,

MSI
Marvin Seife, M.D.
Director
Division of Generic Drug Monographs
Office of Drug Monographs
Bureau of Drugs

Food and Cosmetic Act should be in accordance with this notice. The interested holders of the new-drug applications for these drugs have been mailed a copy of the Academy's report. Any other interested person may obtain a copy of these reports by request to the Food and Drug Administration, Press Relations Office, 200 C Street SW., Washington, D.C. 20204.

Communications forwarded in response to this announcement should be identified with the reference number DESI 12024, directed to the attention of the appropriate office listed below, and addressed to the Food and Drug Administration, 5600 Fishers Lane, Rockville, Md. 20852.

Supplements (Identify with NDA number): Office of Scientific Evaluation (ED-100), Bureau of Drugs.

Original new-drug applications: Office of Scientific Evaluation (ED-100), Bureau of Drugs.

All other communications regarding this announcement: Drug Efficacy Study Implementation Project Office (BD-5), Bureau of Drugs.

This notice is issued pursuant to provisions of the Federal Food, Drug, and Cosmetic Act (secs. 502, 505, 52 Stat. 1050-53, as amended; 21 U.S.C. 352, 355) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 2.120).

Dated: February 8, 1971.

SAM D. FINE,
Associate Commissioner
for Compliance.

[FR Doc. 71-3227 Filed 3-8-71; 8:46 am]

[DESI 10126]

POLYOXYETHYLENE DODECANOL, MENTHOL, CAMPHOR, EUCALYPTUS OIL, AND BENZOIN FOR INHALATION

Drugs for Human Use; Drug Efficacy Study Implementation

The Food and Drug Administration has evaluated a report received from the National Academy of Sciences-National Research Council, Drug Efficacy Study Group, on the following drug:

Vicks Vaposteam Liquid, containing polyoxyethylene dodecanol, menthol, camphor, eucalyptus oil, and benzoin tincture; marketed by Vick Chemical Co., Division of Richardson-Merrell, Inc., 1 Bradford Road, Mount Vernon, N.Y. 10017 (NDA 10-126).

The drug is regarded as a new drug. The effectiveness classification and marketing status are described below.

A. Effectiveness classification. The Food and Drug Administration has considered the Academy's report and concludes that this over-the-counter drug is possibly effective when administered as an inhalant in steam for the relief of cough, stuffiness, and chest congestion.

B. Marketing status. 1. Holders of previously approved new-drug applications and any person marketing any such drug

without approval will be allowed 6 months from the date of publication of this announcement in the FEDERAL REGISTER to obtain and submit in a supplemental or original new-drug application data to provide substantial evidence of effectiveness for those indications for which the drug has been classified as possibly effective. To be acceptable for consideration in support of the effectiveness of a drug, any such data must be previously unsubmitted, well-organized, and include data from adequate and well-controlled clinical investigations (identified for ready review) as described in § 130.11 and 5 of the regulations published in the FEDERAL REGISTER of May 8, 1970 (35 FR. 7230). Carefully conducted and documented clinical studies obtained under uncontrolled or partially controlled conditions are not acceptable as a sole basis for the approval of claims of effectiveness, but such studies may be considered in their merits for corroborative support of efficacy and evidence of safety.

2. At the end of the 6-month period, any such data will be evaluated to determine whether there is substantial evidence of effectiveness for such uses. After that evaluation, the conclusions concerning the drug will be published in the FEDERAL REGISTER. If no studies have been undertaken or if the studies do not provide substantial evidence of effectiveness, procedures will be initiated to withdraw approval of the new-drug applications for such drugs, pursuant to the provisions of section 505(e) of the Federal Food, Drug, and Cosmetic Act. Withdrawal of approval of the applications will cause any such drugs on the market to be new drugs for which an approval is required.

The above-named holder of the new-drug application for this drug has been mailed a copy of the NAS-NRC report. Any interested person may obtain a copy of the report by writing to the applicable office named below.

Communications forwarded in response to this announcement should be identified with the reference number DESI 10126, directed to the attention of the following appropriate office, and addressed (unless otherwise specified) to the Food and Drug Administration, 5600 Fishers Lane, Rockville, Md. 20852:

Supplements (Identify with NDA number): Office of Scientific Evaluation (ED-100), Bureau of Drugs.

Original new-drug applications: Office of Scientific Evaluation (ED-100), Bureau of Drugs.

Requests for NAS-NRC Reports: Press Relations Office, Food and Drug Administration (CE-200), 200 C Street SW., Washington, D.C. 20204.

All other communications regarding this announcement: Drug Efficacy Study Implementation Project Office (BD-5), Bureau of Drugs.

This notice is issued pursuant to provisions of the Federal Food, Drug, and Cosmetic Act (secs. 502, 505, 52 Stat. 1050-53, as amended; 21 U.S.C. 352, 355) and under authority delegated to the

Commissioner of Food and Drugs (21 CFR 2.120).

Dated: February 8, 1971.

CHARLES C. EDWARDS,
Commissioner of Food and Drugs.

[FR Doc. 71-3226 Filed 3-8-71; 8:46 am]

[DESI 7898]

PROBENECID

Drugs for Human Use; Drug Efficacy Study Implementation

The Food and Drug Administration has evaluated a report received from the National Academy of Sciences-National Research Council, Drug Efficacy Study Group, on the following drug:

Benemid Tablets containing probenecid; Merck, Sharp and Dohme, Division of Merck and Co., Inc., West Point, Pa. 19486 (NDN 7-898).

The drug is regarded as a new drug (21 U.S.C. 321(p)). Supplemental new-drug applications are required to revise the labeling in and to update previously approved applications providing for such drugs. A new-drug application is required from any person marketing such drug without approval.

The Food and Drug Administration is prepared to approve new-drug applications and supplements to previously approved new-drug applications under conditions described in this announcement.

A. Effectiveness classification. The Food and Drug Administration has considered the Academy's report, as well as other available evidence, and concludes that this drug is effective for the indications described in the labeling conditions which follow.

B. Form of drug. This preparation is in tablet form suitable for oral administration.

C. Labeling conditions. 1. The label bears the statement "Caution: Federal law prohibits dispensing without prescription."

2. The drug is labeled to comply with all requirements of the Act and regulations. Its labeling bears adequate information for safe and effective use of the drug and is in accord with the guidelines for uniform labeling published in the FEDERAL REGISTER of February 6, 1970. The "Indications" section is as follows:

INDICATIONS

For the treatment of gout and gouty arthritis.

As an adjuvant to therapy with penicillin G, O, or V for elevation and prolongation of penicillin plasma levels by whatever route the antibiotic is given.

D. Previously approved applications. 1. Each holder of a "deemed approved" new-drug application (i.e., an application which became effective on the basis of safety prior to October 10, 1962) for such drug is requested to seek approval of the claims of effectiveness and bring the application into conformance by submitting supplements containing:

a. Revised labeling as needed to conform to the labeling conditions described herein for the drug and complete current container labeling, unless recently submitted.

b. Adequate data to assure the biologic availability of the drug in the formulation which is marketed. If such data are already included in the application, specific reference thereto may be made.

c. Updating information as needed to make the application current in regard to items 6 (components), 7 (composition), and 8 (methods, facilities, and controls) of the new-drug application form FD-355II to the extent described for abbreviated new-drug applications, § 130.4(f), published in the FEDERAL REGISTER of April 24, 1970 (35 F.R. 6574). (One supplement may contain all the information described in this paragraph.)

2. Such supplements should be submitted within the following periods after the date of publication of this notice in the FEDERAL REGISTER:

a. 60 days for revised labeling—the supplement should be submitted under the provisions of § 130.9 (d) and (e) of the new-drug regulations (21 CFR 130.9) which permit certain changes to be put into effect at the earliest possible time.
b. 180 days for biologic availability data.

c. 60 days for updating information.

3. Marketing of the drug may continue until the supplemental applications submitted in accord with the preceding subparagraphs 1 and 2 are acted upon, provided that within 60 days after the date of this publication, the labeling of the preparation shipped within the jurisdiction of the Act is in accord with the labeling conditions described in this announcement.

E. New applications. 1. Any other person who distributes or intends to distribute such drug which is intended for the conditions of use for which it has been shown to be effective, as described under A above, should submit an abbreviated new-drug application meeting the conditions specified in § 130.4(f) (1), (2), and (3), published in the FEDERAL REGISTER of April 24, 1970 (35 F.R. 6574). Such applications should include proposed labeling which is in accord with the labeling conditions described herein and adequate data to assure the biologic availability of the drug in the formulation which is marketed or proposed for marketing.

2. Distribution of any such preparation currently on the market without an approved new-drug application may be continued provided that:

a. Within 60 days from the date of publication of this announcement in the FEDERAL REGISTER, the labeling of such preparation shipped within the jurisdiction of the Act is in accord with the labeling conditions described herein.

b. The manufacturer, packer, or distributor of such drugs submits, within 180 days from the date of this publication, a new-drug application to the Food and Drug Administration.

c. The applicant submits within a reasonable time additional information that may be required for the approval of the application as specified in a written communication from the Food and Drug Administration.

d. The application has not been ruled incomplete or unapprovable.

F. Exemption from periodic reporting. The periodic reporting requirements of §§ 130.25 a and 130.13(b) (4) are waived in regard to applications approved for this drug solely for the conditions of use for which the drug is regarded as effective as defined herein. The requirements of §§ 130.25(d) and 130.13(b) (1), (2), and (3) remain a continuing responsibility of each applicant.

G. Unapproved use or form of drug. If the article is labeled or advertised for use in any condition other than those provided for in this announcement, it may be regarded as an unapproved new drug subject to regulatory proceedings until such recommended use is approved in a new-drug application or is otherwise in accord with this announcement.

2. If the article is proposed for marketing in another form or for a use other than the use provided for in this announcement appropriate additional information as described in § 130.4 or § 130.9 of the regulations (21 CFR 130.4, 130.9) may be required, including results of animal and clinical tests intended to show whether the drug is safe and effective.

A copy of the Academy's report has been furnished to the firm referred to above. Any other interested person may obtain a copy on request to the Food and Drug Administration, Press Relations Office (CE-200), 200 C Street SW., Washington, D.C. 20204.

Communications forwarded in response to this announcement should be identified with the reference number DESI 7009, directed to the attention of the appropriate office listed below, and addressed to the Food and Drug Administration, 5500 Fishers Lane, Rockville, Md. 20852:

Supplements (identify with NDA number):
Office of Scientific Evaluation (BD-100),
Bureau of Drugs.

Original abbreviated new-drug applications (identify as such): Drug Efficacy Study Implementation Project Office (BD-5), Bureau of Drugs.

All other communications regarding this announcement: Drug Efficacy Study Implementation Project Office (BD-5), Bureau of Drugs.

This notice is issued pursuant to provisions of the Federal Food, Drug, and Cosmetic Act (secs. 502, 505, 52 Stat. 1050-53, as amended; 21 U.S.C. 352, 355) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 2.100).

Dated: February 8, 1971.

SAM D. FINE,
Associate Commissioner
for Compliance.

[PR Doc. 71-324 Filed 3-8-71; 8:46 am]

ATOMIC ENERGY COMMISSION

URANIUM ENRICHMENT SERVICES CRITERIA

Charge for Enriching Services

The U.S. Atomic Energy Commission (AEC) hereby announces revisions to the notice entitled "Uranium Enrichment Services Criteria" as published in the FEDERAL REGISTER on December 23, 1966 (31 F.R. 16479), and as amended in 35 F.R. 13546 of August 23, 1970 (referred to herein as the notice).

1. Subparagraphs 5(c) (1), (2), and (3) of the notice are revised to read as follows:

(c) Charge for enriching services. (1) The charge for enriching services, in accordance with the Act, will be established on a nondiscriminatory basis and on a basis of recovery of the Government's costs over a reasonable period of time. Applicable charges for enriching services and related services will be those in effect at the time of delivery of enriched uranium to the customer as published in the FEDERAL REGISTER, or, in the absence of such publication, determined in accordance with the Commission's pricing policy. The charge per unit of separative work for enriching services will be the same as that employed in the Commission's published schedule of charges for sale or lease of enriched uranium. The AEC may impose an appropriate surcharge representing additional costs, if any, to the AEC for providing approving services on such dates.

(2) AEC's charge for enriching services will be established on a basis that will assure the recovery of appropriate Government costs projected over a reasonable period of time. The cost of separative work includes electric power and all other costs, direct and indirect, of operating the gaseous diffusion plants; appropriate depreciation of said plants; and a factor to cover applicable costs of process development, AEC administration and other Government support functions, and imputed interest on investment in plant and working capital. During the early period of growth of nuclear power, there will be only a small civilian demand on the large AEC diffusion plants. These plants were originally constructed for national security purposes, but will be utilized in meeting future civilian requirements. In this interim period of low plant utilization, the Commission has determined that the costs to be charged to the separative work produced for civilian customers will exclude those portions of the costs attributable to depreciation and interest on plant investment which are properly allocable to plant in standby and to excess capacity.

(3) Projections of supply and demand over a reasonable time period will be used in establishing a plan for diffusion plant operations. This plan will be the basis for establishing an average charge

CHELSEA LABORATORIES, INC.

428 DOUGHTY BLVD. · INWOOD, N. Y. 11696 · (516) 239-3200

ABBREVIATED
NEW DRUG APPLICATION
85-552

DEC 14 1976

Marvin Seife, M.D., Director
Division of Generic Drug Monographs
Office of Drug Monographs
Bureau of Drugs (HFD 530-Rm. 16-72)
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20852

Dear Dr. Seife:

Re: Abbreviated New Drug Application

Product: Probenecid 500 mg. with Colchicine 0.5 mg. Tablets

Pursuant to Section 505(b) of the Federal Food, Drug and Cosmetic Act we are submitting herewith an abbreviated new drug application for the drug referred supra.

Included in this submission are:

1. Form 356H
2. Volume No. 1 - Copy No. 1 (Blue folder)
3. Volume No. 1 - Copy No. 2 (Red folder)
4. Volume No. 1 - Copy No. 3 (Yellow folder)

Respectfully yours,


~~Nat Getroldman~~, President
Chelsea Laboratories, Inc.

SG /cat
Enclosures



NEW DRUG APPLICATION (DRUGS FOR HUMAN USE)

(Title 21, Code of Federal Regulations, § 314.1)

Name of applicant Chelsea Laboratories, Inc.

Address 428 Doughty Blvd., Inwood, N.Y. 11696

Date DEC 14 1976

Name of new drug Probenecid 500 mg. with Colchicine 0.5 mg. Tablets


- Original application (regulation § 314.1).
 Amendment to original, unapproved application (regulation § 314.8)
 Abbreviated application (regulation § 314.1(f)).
 Amendment to abbreviated, unapproved application (regulation § 314.8).
 Supplement to an approved application (regulation § 314.8).
 Amendment to supplement to an approved application.

The undersigned submits this application for a new drug pursuant to section 505(b) of the Federal Food, Drug, and Cosmetic Act. It is understood that when this application is approved, the labeling and advertising for the drug will prescribe, recommend, or suggest its use only under the conditions stated in the labeling which is part of this application; and if the article is a prescription drug, it is understood that any labeling which furnishes or purports to furnish information for use or which prescribes, recommends, or suggests a dosage for use of the drug will contain the same information for its use, including indications, effects, dosages, routes, methods, and frequency and duration of administration, any relevant warnings, hazards, contraindications, side effects, and precautions, as that contained in the labeling which is part of this application in accord with §201.100 (21 CFR 201.100). It is understood that all representations in this application apply to the drug produced until an approved supplement to the application is received, and that any change or the change is made in conformance with other provisions of §314.8 of the new-drug regulation.

Attached hereto, submitted in the form described in §314.1(e) of the new-drug regulations, and constituting a part of this application are the following:

1. Table of contents. The table of contents should include the volume number and the page number in which the complete and detailed item is located and the volume number and page number in which the summary of that item is located (if any).
2. Summary. A summary demonstrating that the application is well-organized, adequately tabulated, statistically analyzed (where appropriate), and coherent and that it presents a sound basis for the approval requested. The summary should include the following information: (In lieu of the outline described below and the evaluation described in Item 3, and expanded summary and evaluation as outlined in §314.1(d) of the new-drug regulations may be submitted to facilitate the review of this application.)
 - a. Chemistry.
 - i. Chemical structural formula or description for any new-drug substance.
 - ii. Relationship to other chemically or pharmacologically related drugs.
 - iii. Description of dosage form and quantitative composition.
 - b. Scientific rationale and purpose the drug is to serve.
 - c. Reference number of the investigational drug notice(s) under which this drug was investigated and of any notice, new-drug application, or master file of which any contents are being incorporated by reference to support this application.
 - d. Preclinical studies. (Present all findings including all adverse experiences which may be interpreted as incidental or not drug-related. Refer to date and page number of the investigational drug notice(s) or the volume and page number of this application where complete data and reports appear.)
 - i. Pharmacology (pharmacodynamics, endocrinology, metabolism, etc.).
 - ii. Toxicology and pathology: Acute toxicity studies; subacute and chronic toxicity studies; reproduction and teratology studies; miscellaneous studies.

- iii. Clinical studies. (All material should refer specifically to the clinical investigator and to the volume and page number in the application and any documents incorporated by reference where the complete data and reports may be found.)
 - i. Specific studies not described elsewhere.
 - ii. Dosage studies.
 - iii. Controlled clinical studies.
 - iv. Other clinical studies (for example, uncontrolled or incompletely controlled studies).
 - v. Clinical laboratory studies related to effectiveness.
 - vi. Clinical laboratory studies related to safety.
 - vii. Summary of literature and unpublished reports available to the applicant.
3. Evaluation of safety and effectiveness. a. Summarize separately the favorable and unfavorable evidence for each claim in the package labeling. Include references to the volume and page number in the application and in any documents incorporated by reference where the complete data and reports may be found.
 - b. Include tabulation of all side effects or adverse experience, by age, sex, and dosage formulation, whether or not considered to be significant, showing whether administration of the drug was stopped and showing the investigator's name with a reference to the volume and page number in the application and any documents incorporated by reference where the complete data and reports may be found. Indicate those side effects or adverse experiences considered to be drug-related.
4. Copies of the label and all other labeling to be used for the drug (a total of 12 copies if in final printed form, 4 copies if in draft form):
 - a. Each label, or other labeling, should be clearly identified to show its position on, or the manner in which it accompanies, the market package.



b. If the drug is to be offered over the counter, labeling on or within the retail package should include adequate directions for use by the layman under all the conditions for which the drug is intended for lay use or is to be prescribed, recommended, or suggested in any labeling or advertising sponsored by or on behalf of the applicant and directed to the layman. If the drug is intended or offered for uses under the professional supervision of a practitioner licensed by law to administer it, the application should also contain labeling that includes adequate information for all such uses, including all the purposes for which the over-the-counter drug is to be advertised to, or represented for use by, physicians.

c. If the drug is limited in its labeling to use under the professional supervision of a practitioner licensed by law to administer it, its labeling should bear information for use under which such practitioners can use the drug for the purposes for which it is intended, including all the purposes for which it is to be advertised or represented, in accord with §201.100 (21 CFR 201.100). The application should include any labeling for the drug intended to be made available to the layman.

d. If no established name exists for a new-drug substance, the application shall propose a nonproprietary name for use as the established name for the substance.

e. Typewritten or other draft labeling copy may be submitted for preliminary consideration of an application. An application will not ordinarily be approved prior to the submission of the final printed label and labeling of the drug.

f. No application may be approved if the labeling is false or misleading in any particular.

When mailing pieces, any other labeling, or advertising copy are devised for promotion of the new drug, samples shall be submitted at the time of initial dissemination of such labeling and at the time of initial placement of any such advertising for a prescription drug (see §310.300 of the new-drug regulations). Approval of a supplemental new-drug application is required prior to use of any promotional claims not covered by the approved application.)

5. A statement as to whether the drug is (or is not) limited in its labeling and by this application to use under the professional supervision of a practitioner licensed by law to administer it.

6. A full list of the articles used as components of the drug. This list should include all substances used in the synthesis, extraction, or other method of preparation of any new-drug substance, and in the preparation of the finished dosage form, regardless of whether they undergo chemical change or are removed in the process. Each substance should be identified by its established name, if any, or complete chemical name, using structural formulas when necessary for specific identification. If any proprietary preparation is used as a component, the proprietary name should be followed by a complete quantitative statement of composition. Reasonable alternatives for any listed substance may be specified.

7. A full statement of the composition of the drug. The statement shall set forth the name and amount of each ingredient, whether active or not, contained in a stated quantity of the drug in the form in which it is to be distributed (for example, amount per tablet or per milliliter) and a batch formula representative of that to be employed for the manufacture of the finished dosage form. All components should be included in the batch formula regardless of whether they appear in the finished product. Any calculated excess of an ingredient over the label declaration should be designated as such and percent excess shown. Reasonable variations may be specified.

8. A full description of the methods used in, and the facilities and controls used for, the manufacture, processing, and packing of drug. Included in this description should be full information with respect to any new-drug substance and to the new-drug dosage form, as follows, in sufficient detail to permit evaluation of the adequacy of the described methods of manufacture, processing, and packing and the described facilities and controls to determine and preserve the identity, strength, quality, and purity of the drug:

a. A description of the physical facilities including building and equipment used in manufacturing, processing, packaging, labeling, storage, and control operations.

b. A description of the qualifications, including educational background and experience, of the technical and professional personnel who are responsible for assuring that the drug has the safety, identity, strength, quality, and purity it purports or is represented to possess, and a statement of their responsibilities.

c. The methods used in the synthesis, extraction, isolation, or purification of any new-drug substance. When the specifications and control applied to such substance are inadequate in themselves to determine its identity, strength, quality, and purity, the methods should be described in sufficient detail, including quantities used, times, temperatures, pH, solvents, etc., to determine these characteristics. Alternative methods or variations in methods within reasonable limits that do not affect such characteristics of the substance may be specified.

d. Precautions to assure proper, identity, strength, quality, and purity of the raw materials, whether active or not, including the specifications for acceptance and methods of testing for each lot of raw material.

e. Whether or not each lot of raw materials is given a serial number to identify it, and the use made of such numbers in subsequent plant operations.

f. If the applicant does not himself perform all the manufacturing, processing, packaging, labeling, and control operations for any new-drug substance or the new-drug dosage form, his statement identifying each person who will perform any part of such operations and designating the part; and a signed statement from each such person fully describing, directly or by reference, the methods, facilities, and controls in his part of the operation.

g. Method of preparation of the master formula records and individual batch records and manner in which these records are used.

h. The instructions used in the manufacturing, processing, packaging, and labeling of each dosage form of the new drug, including any special precautions observed in the operations.

i. Adequate information with respect to the characteristics of and the test methods employed for the container, closure, or other component parts of the drug package to assure their suitability for the intended use.

j. Number of individuals checking weight or volume of each individual ingredient entering into each batch of the drug.

k. Whether or not the total weight or volume of each batch is determined at any stage of the manufacturing process subsequent to making up a batch according to the formula card and, if so, at what stage and by whom it is done.

l. Precautions to check the actual package yield produced from a batch of the drug with the theoretical yield. This should include a description of the accounting for such items as discards, breakage, etc., and the criteria used in accepting or rejecting batches of drugs in the event of an unexplained discrepancy.

m. Precautions to assure that each lot of the drug is packaged with the proper label and labeling, including provisions for labeling storage and inventory control.

n. The analytical controls used during the various stages of the manufacturing, processing, packaging, and labeling of the drug, including a detailed description of the collection of samples and the analytical procedures to which they are subjected. The analytical procedures should be capable of determining the active components within a reasonable degree of accuracy and of assuring the identity of such components. If the article is one that is represented to be sterile, the same information with regard to the manufacturing, processing, packaging, and the collection of samples of the drug should be given for sterility controls. Include the standards used for acceptance of each lot of the finished drug.

o. An explanation of the exact significance of the batch control numbers used in the manufacturing, processing, packaging, and labeling of the drug, including the control numbers that appear on the label of the finished article. State whether these numbers enable determination of the complete manufacturing

history of the product. Describe any methods used to permit determination of the distribution of any batch; if its recall is required.

p. A complete description of, and data derived from, studies of the stability of the drug, including information showing the suitability of the analytical method used. Describe any additional stability studies underway or contemplated. Stability data should be submitted for any new-drug substance, for the finished dosage form of the drug in the container in which it is to be marketed, including any proposed multiple-dose container, and if it is to be put into solution at the time of dispensing, for the solution prepared as directed. State the expiration date(s) that will be used on the label to preserve the identity, strength, quality, and purity of the drug until it is used. (If no expiration date is proposed, the applicant must justify its absence.)

q. Additional procedures employed which are designed to prevent contamination and otherwise assure proper control of the product.

(An application may be refused unless it includes adequate information showing that the methods used in, and the facilities and controls used for, the manufacturing, processing, and packaging of the drug are adequate to preserve its identity, strength, quality, and purity in conformity with good manufacturing practice and identifies each establishment, showing the location of the plant conducting these operations.)

9. Samples of the drug and articles used as components, as follows: a. The following samples shall be submitted with the application or as soon thereafter as they become available. Each sample shall consist of four identical, separately packaged subdivisions, each containing at least three times the amount required to perform the laboratory test procedures described in the application to determine compliance with its control specifications for identity and assays:

i. A representative sample or samples of the finished dosage form(s) proposed in the application and employed in the clinical investigations and a representative sample or samples of each new-drug substance, as defined in §310.3(g), from the batch(es) employed in the production of such dosage form(s).

ii. A representative sample or samples of finished market packages of each dosage form of the drug prepared for initial marketing and, if any such sample is not from a commercial-scale production batch, such a sample from a representative commercial-scale production batch; and a representative sample or samples of each new-drug substance as defined in §310.3(g) of the new-drug regulations, from the batch(es) employed in the production of such dosage form(s).

iii. A sample or samples of any reference standard and blank used in the procedures described in the application for assaying each new-drug substance and other assayed components of the finished drug; *Provided, however,* That samples of reference standards recognized in the official U.S. Pharmacopeia or The National Formulary need not be submitted unless requested.

b. Additional samples shall be submitted on request.

c. Each of the samples submitted shall be appropriately packaged and labeled to preserve its characteristics, to identify the material and the quantity in each subdivision of the sample, and to identify each subdivision with name of the applicant and the new-drug application to which it relates.

d. There shall be included a full list of the samples submitted pursuant to Item 9a; a statement of the additional samples that will be submitted as soon as available; and, with respect to each sample submitted, full information with respect to its identity, the origin of any new-drug substance contained therein (including in the case of new-drug substances, a statement whether it was produced on a laboratory, pilot-plant, or full-production scale) and detailed results of all laboratory tests made to determine the identity, strength, quality, and purity of the batch represented by the sample, including assays. Include for any reference standard a complete description of its preparation and the results of all laboratory tests on it. If the test methods used differed from those described in the application, full details of the methods employed

in obtaining the reported results shall be submitted.

e. The requirements of Item 9a may be waived in whole or in part on request of the applicant or otherwise when any such samples are not necessary.

f. If samples of the drug are sent under separate cover, they should be addressed to the attention of the Bureau of Drugs and identified on the outside of the shipping carton with the name of the applicant and the name of the drug as shown on the application.

10. Full reports of preclinical investigations that have been made to show whether or not the drug is safe for use and effective use. a. An application may be refused unless it contains full reports of adequate preclinical tests by all methods reasonably applicable to a determination of the safety and effectiveness of the drug under the conditions of use suggested in the proposed labeling.

b. Detailed reports of the preclinical investigations, including all studies made on laboratory animals, the methods used, and the results obtained, should be clearly set forth. Such information should include identification of the person who conducted each investigation, a statement of where the investigations were conducted, and where the underlying data are available for inspection. The animal studies may not be considered adequate unless they give proper attention to the conditions of use recommended in the proposed labeling for the drug such as, for example, whether the drug is for short- or long-term administration or whether it is to be used in infants, children, pregnant women, or women of child-bearing potential.

c. Detailed reports of any pertinent microbiological and in vitro studies.

d. Summarize and provide a list of literature references (if available) to all other preclinical information known to the applicant, whether published or unpublished, that is pertinent to an evaluation of the safety or effectiveness of the drug.

11. List of investigators. a. A complete list of all investigators supplied with the drug including the name and post office address of each investigator and, following each name, the volume and page references to the investigator's report(s) in this application and in any documents incorporated by reference, or the explanation of the omission of any reports.

b. The unexplained omission of any reports of investigations made with the new drug by the applicant, or submitted to him by an investigator, or the unexplained omission of any pertinent reports of investigations or clinical experience received or otherwise obtained by the applicant from published literature or other sources, whether or not it would bias an evaluation of the safety of the drug or its effectiveness in use, may constitute grounds for the refusal or withdrawal of the approval of an application.

12. Full reports of clinical investigations that have been made to show whether or not the drug is safe for use and effective in use. a. An application may be refused unless it contains full reports of adequate tests by all methods reasonably applicable to show whether or not the drug is safe and effective for use as suggested in the labeling.

b. An application may be refused unless it includes substantial evidence consisting of adequate and well-controlled investigations, including clinical investigations, by experts qualified by scientific training and experience to evaluate the effectiveness of the drug involved, on the basis of which it could fairly and responsibly be concluded by such experts that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, recommended, or suggested in the proposed labeling.

c. Reports of all clinical tests sponsored by the applicant or received or otherwise obtained by the applicant should be attached. These reports should include adequate information concerning each subject treated with the drug or employed as a control, including age, sex, conditions treated, dosage, frequency of administration of the drug, results of all relevant clinical observations and laboratory examinations made, full information

concerning any other treatment given previously or concurrently, and a full statement of adverse effects and useful results observed, together with an opinion as to whether such effects or results are attributable to the drug under investigation and a statement of where the underlying data are available for inspection. Ordinarily, the reports of clinical studies will not be regarded as adequate unless they include reports from more than one independent, competent investigator who maintains adequate case histories of an adequate number of subjects, designed to record observations and permit evaluation of any and all discernible effects attributable to the drug in each individual treated and comparable records on any individuals employed as controls. An application for a combination drug may be refused unless there is substantial evidence that each ingredient designated as active makes a contribution to the total effect claimed for the drug combination. Except when the disease for which the drug is being tested occurs with such infrequency in the United States as to make testing impractical, some of the investigations should be performed by competent investigators within the United States.

d. Attach as a separate section a completed Form FD-1639, Drug Experience Report (obtainable, with instructions, on request from the Food and Drug Administration, Department of HEW, 5600 Fishers Lane, Rockville, Maryland 20852), for each adverse experience or, if feasible, for each subject or patient experiencing one or more adverse effects, described in Item 12c, whether or not full information is available. Form FD-1639 should be prepared by the applicant if the adverse experience was not reported in such form by the investigator. The Drug Experience Report should be cross-referenced to any narrative description included in Item 12c. In lieu of a FD Form 1639, a computer-generated report may be submitted if equivalent in all elements of information with the identical enumerated sequence of events and methods of completion; all formats proposed for such use will require initial review and approval by the Food and Drug Administration.

e. All information pertinent to an evaluation of the safety and effectiveness of the drug received or otherwise obtained by the

applicant from any source, including information derived from other investigations or commercial marketing (for example, outside the United States), or reports in the scientific literature, involving the drug that is the subject of the application and related drugs. An adequate summary may be acceptable in lieu of a reprint of a published report which only supports other data submitted. Reprints are not required of reports in designated journals, listed in §310.9 of the new-drug regulations, about related drugs; a bibliography will suffice. Include the evaluation of the safety or effectiveness of the drug that has been made by the applicant's medical department, expert committee, or consultants.

f. If the drug is a combination of previously investigated or marketed drugs, an adequate summary of preexisting information from preclinical and clinical investigation and experience with its components, including all reports received or otherwise obtained by the applicant suggesting side effects, contraindications, and ineffectiveness in use of such components. Such summary should include an adequate bibliography of publications about the components and may incorporate by reference information concerning such components previously submitted by the applicant to the Food and Drug Administration.

g. The complete composition and/or method of manufacture of the new drug used in each submitted report of investigation should be shown to the extent necessary to establish its identity, strength, quality, and purity if it differs from the description in Item 6, 7, or 8 of the application.

13. If this is a supplemental application, full information on each proposed change concerning any statement made in the approved application. Observe the provisions of §314.8 of the new-drug regulations concerning supplemental applications.

14. [Reserved]

15. The applicant is required to submit an environmental impact analysis report analyzing the environmental impact of the manufacturing process and the ultimate use or consumption of the drug pursuant to §6.1 of this chapter.

Chelsea Laboratories, Inc.

(Applicant)

Per

Nat Getrajdman

(Responsible Official or agent)

President

(Indicate authority)

(Warning: A willfully false statement is a criminal offense. U.S.C. Title 18, sec. 1001.)

Note: This application must be signed by the applicant or by an authorized attorney, agent, or official. If the applicant or such authorized representative does not reside or have a place of business within the United States, the application must also furnish the name and post office address of and must be countersigned by an authorized attorney, agent, or official residing or maintaining a place of business within the United States.

CHELSEA LABORATORIES, INC.

428 DOUGHTY BLVD. · INWOOD, N. Y. 11696 · (516) 239-3200

*Rec w/F
DMS*

NDA #85-552

JUL 1 1977

Marvin Seife, M.D., Director
Division of Generic Drug Monographs
Office of Drug Monographs
Bureau of Drugs (HFD 530 - Rm.16-72)
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20852

RESUBMISSION
NDA ORIG AMENDMENT

Dear Dr. Seife:

Re: Amendment to Abbreviated, Unapproved Application
Product:

Probenecid 500 mg. with Colchicine 0.5 mg. Tablets

Chelsea Laboratories, Inc. is submitting the information requested in your letter of February 9, 1977, in order to reach a decision concerning final approval of the Abbreviated New Drug Application submitted for the drug referred supra.

1. Attached is requested information on Containers.
2. See attached for further information on the "extremely poisonous" nature of Colchicine.
3. Samples of the final dosage form along with our analytical results for their testing are herewith enclosed.
4. We hereby certify that a stability study will be performed on the first three (3) marketing batches of Probenecid 500 mg. with Colchicine 0.5 mg. Tablets and the data will be submitted as it becomes available.

This newly submitted information should facilitate the review of our application. Thank you for your prompt attention to this information.

Cordially yours,

Not Getrajan
Nat Getrajan, President
Chelsea Laboratories, Inc.

RECEIVED
JUL 11 1977

NG/cat

Encls.

NEW DRUG APPLICATION (DRUGS FOR HUMAN USE)

(Title 21, Code of Federal Regulations, § 314.1)

Name of applicant Chelsea Laboratories, Inc.
Address 428 Doughty Blvd., Inwood, N.Y. 11696
Date JUL 1 1977
Name of new drug Probenecid 500 mg. w/ Colchicine 0.5 mg. Tab. (NDA#85-552)

- Original application (regulation § 314.1).
 Amendment to original, unapproved application (regulation § 314.8)
 Abbreviated application (regulation § 314.1(f)).
- Amendment to abbreviated, unapproved application (regulation § 314.8).
 Supplement to an approved application (regulation § 314.8).
 Amendment to supplement to an approved application.

The undersigned submits this application for a new drug pursuant to section 505(b) of the Federal Food, Drug, and Cosmetic Act. It is understood that when this application is approved, the labeling and advertising for the drug will prescribe, recommend, or suggest its use only under the conditions stated in the labeling which is part of this application; and if the article is a prescription drug, it is understood that any labeling which furnishes or purports to furnish information for use or which prescribes, recommends, or suggests a dosage for use of the drug will contain the same information for its use, including indications, effects, dosages, routes, methods, and frequency and duration of administration, any relevant warnings, hazards, contraindications, side effects, and precautions, as that contained in the labeling which is part of this application in accord with §201.100 (21 CFR 201.100). It is understood that all representations in this application apply to the drug produced until an approved supplement to the application provides for a change or the change is made in conformance with other provisions of §314.8 of the new-drug regulations.

Attached hereto, submitted in the form described in §314.1(e) of the new-drug regulations, and constituting a part of this application are the following:

1. Table of contents. The table of contents should specify the volume number and the page number in which the complete and detailed item is located and the volume number and the page number in which the summary of that item is located (if any).
2. Summary. A summary demonstrating that the application is well-organized, adequately tabulated, statistically analyzed (where appropriate), and coherent and that it presents a sound basis for the approval requested. The summary should include the following information: (In lieu of the outline described below and the evaluation described in Item 3, and expanded summary and evaluation as outlined in §314.1(d) of the new-drug regulations may be submitted to facilitate the review of this application.)
 - a. Chemistry.
 - i. Chemical structural formula or description for any new-drug substance.
 - ii. Relationship to other chemically or pharmacologically related drugs.
 - iii. Description of dosage form and quantitative composition.
 - b. Scientific rationale and purpose the drug is to serve.
 - c. Reference number of the investigational drug notice(s) under which this drug was investigated and of any notice, new-drug application, or master file of which any contents are being incorporated by reference to support this application.
 - d. Preclinical studies. (Present all findings including all adverse experiences which may be interpreted as incidental or not drug-related. Refer to date and page number of the investigational drug notice(s) or the volume and page number of this application where complete data and reports appear.)
 - i. Pharmacology (pharmacodynamics, endocrinology, metabolism, etc.).
 - ii. Toxicology and pathology: Acute toxicity studies; subacute and chronic toxicity studies; reproduction and teratology studies; miscellaneous studies.

- a. Clinical studies. (All material should refer specifically to each clinical investigator and to the volume and page number in the application and any documents incorporated by reference where the complete data and reports may be found.)
 - i. Special studies not described elsewhere.
 - ii. Dose-range studies.
 - iii. Controlled clinical studies.
 - iv. Other clinical studies (for example, uncontrolled or incompletely controlled studies).
 - v. Clinical laboratory studies related to effectiveness.
 - vi. Clinical laboratory studies related to safety.
 - vii. Summary of literature and unpublished reports available to the applicant.
3. Evaluation of safety and effectiveness.
 - a. Summarize separately the favorable and unfavorable evidence for each claim in the package labeling. Include references to the volume and page number in the application and in any documents incorporated by reference where the complete data and reports may be found.
 - b. Include tabulation of all side effects or adverse experience, by age, sex, and dosage formulation, whether or not considered to be significant, showing whether administration of the drug was stopped and showing the investigator's name with a reference to the volume and page number in the application and any documents incorporated by reference where the complete data and reports may be found. Indicate those side effects or adverse experiences considered to be drug-related.
4. Copies of the label and all other labeling to be used for the drug (a total of 12 copies if in final printed form, 4 copies if in draft form):
 - a. Each label, or other labeling, should be clearly identified to show its position on, or the manner in which it accompanies, the market package.

b. If the drug is to be offered over the counter, labeling on or within the retail package should include adequate directions for use by the layman under all the conditions for which the drug is intended for lay use or is to be prescribed, recommended, or suggested in any labeling or advertising sponsored by or on behalf of the applicant and directed to the layman. If the drug is intended or offered for uses under the professional supervision of a practitioner licensed by law to administer it, the application should also contain labeling that includes adequate information for all such uses, including all the purposes for which the over-the-counter drug is to be advertised to, or represented for use by, physicians.

c. If the drug is limited in its labeling to use under the professional supervision of a practitioner licensed by law to administer it, its labeling should bear information for use under which such practitioners can use the drug for the purposes for which it is intended, including all the purposes for which it is to be advertised or represented, in accord with §201.100 (21 CFR 201.100). The application should include any labeling for the drug intended to be made available to the layman.

d. If no established name exists for a new-drug substance, the application shall propose a nonproprietary name for use as the established name for the substance.

e. Typewritten or other draft labeling copy may be submitted for preliminary consideration of an application. An application will not ordinarily be approved prior to the submission of the final printed label and labeling of the drug.

f. No application may be approved if the labeling is false or misleading in any particular.

When mailing pieces, any other labeling, or advertising copy are devised for promotion of the new drug, samples shall be submitted at the time of initial dissemination of such labeling and at the time of initial placement of any such advertising for a prescription drug (see §310.300 of the new-drug regulations). Approval of a supplemental new-drug application is required prior to use of any promotional claims not covered by the approved application.)

5. A statement as to whether the drug is (or is not) limited in its labeling and by this application to use under the professional supervision of a practitioner licensed by law to administer it.

6. A full list of the articles used as components of the drug. This list should include all substances used in the synthesis, extraction, or other method of preparation of any new-drug substance, and in the preparation of the finished dosage form, regardless of whether they undergo chemical change or are removed in the process. Each substance should be identified by its established name, if any, or complete chemical name, using structural formulas when necessary for specific identification. If any proprietary preparation is used as a component, the proprietary name should be followed by a complete quantitative statement of composition. Reasonable alternatives for any listed substance may be specified.

7. A full statement of the composition of the drug. The statement shall set forth the name and amount of each ingredient, whether active or not, contained in a stated quantity of the drug in the form in which it is to be distributed (for example, amount per tablet or per milliliter) and a batch formula representative of that to be employed for the manufacture of the finished dosage form. All components should be included in the batch formula regardless of whether they appear in the finished product. Any calculated excess of an ingredient over the label declaration should be designated as such and percent excess shown. Reasonable variations may be specified.

8. A full description of the methods used in, and the facilities and controls used for, the manufacture, processing, and packing of drug. Included in this description should be full information with respect to any new-drug substance and to the new-drug dosage form, as follows, in sufficient detail to permit evaluation of the adequacy of the described methods of manufacture, processing, and packing and the described facilities and controls to determine and preserve the identity, strength, quality, and purity of the drug:

a. A description of the physical facilities including building and equipment used in manufacturing, processing, packaging, labeling, storage, and control operations.

b. A description of the qualifications, including educational background and experience, of the technical and professional personnel who are responsible for assuring that the drug has the safety, identity, strength, quality, and purity it purports or is represented to possess, and a statement of their responsibilities.

c. The methods used in the synthesis, extraction, isolation, or purification of any new-drug substance. When the specifications and control applied to such substance are inadequate in themselves to determine its identity, strength, quality, and purity, the methods should be described in sufficient detail, including quantities used, times, temperatures, pH, solvents, etc., to determine these characteristics. Alternative methods or variations in methods within reasonable limits that do not affect such characteristics of the substance may be specified.

d. Precautions to assure proper, identity, strength, quality, and purity of the raw materials, whether active or not, including the specifications for acceptance and methods of testing for each lot of raw material.

e. Whether or not each lot of raw materials is given a serial number to identify it, and the use made of such numbers in subsequent plant operations.

f. If the applicant does not himself perform all the manufacturing, processing, packaging, labeling, and control operations for any new-drug substance or the new-drug dosage form, his statement identifying each person who will perform any part of such operations and designating the part; and a signed statement from each such person fully describing, directly or by reference, the methods, facilities, and controls in his part of the operation.

g. Method of preparation of the master formula records and individual batch records and manner in which these records are used.

h. The instructions used in the manufacturing, processing, packaging, and labeling of each dosage form of the new drug, including any special precautions observed in the operations.

i. Adequate information with respect to the characteristics of and the test methods employed for the container, closure, or other component parts of the drug package to assure their suitability for the intended use.

j. Number of individuals checking weight or volume of each individual ingredient entering into each batch of the drug.

k. Whether or not the total weight or volume of each batch is determined at any stage of the manufacturing process subsequent to making up a batch according to the formula card and, if so, at what stage and by whom it is done.

l. Precautions to check the actual package yield produced from a batch of the drug with the theoretical yield. This should include a description of the accounting for such items as discards, breakage, etc., and the criteria used in accepting or rejecting batches of drugs in the event of an unexplained discrepancy.

m. Precautions to assure that each lot of the drug is packaged with the proper label and labeling, including provisions for labeling storage and inventory control.

n. The analytical controls used during the various stages of the manufacturing, processing, packaging, and labeling of the drug, including a detailed description of the collection of samples and the analytical procedures to which they are subjected. The analytical procedures should be capable of determining the active components within a reasonable degree of accuracy and of assuring the identity of such components. If the article is one that is represented to be sterile, the same information with regard to the manufacturing, processing, packaging, and the collection of samples of the drug should be given for sterility controls. Include the standards used for acceptance of each lot of the finished drug.

o. An explanation of the exact significance of the batch control numbers used in the manufacturing, processing, packaging, and labeling of the drug, including the control numbers that appear on the label of the finished article. State whether these numbers enable determination of the complete manufacturing

history of the product. Describe any methods used to permit determination of the distribution of any batch, if its recall is required.

p. A complete description of, and data derived from, studies of the stability of the drug, including information showing the suitability of the analytical method used. Describe any additional stability studies underway or contemplated. Stability data should be submitted for any new-drug substance, for the finished dosage form of the drug in the container in which it is to be marketed, including any proposed multiple-dose container, and if it is to be put into solution at the time of dispensing, for the solution prepared as directed. State the expiration date(s) that will be used on the label to preserve the identity, strength, quality, and purity of the drug until it is used. (If no expiration date is proposed, the applicant must justify its absence.)

q. Additional procedures employed which are designed to prevent contamination and otherwise assure proper control of the product.

(An application may be refused unless it includes adequate information showing that the methods used in, and the facilities and controls used for, the manufacturing, processing, and packaging of the drug are adequate to preserve its identity, strength, quality, and purity in conformity with good manufacturing practice and identifies each establishment, showing the location of the plant conducting these operations.)

9. Samples of the drug and articles used as components, as follows: a. The following samples shall be submitted with the application or as soon thereafter as they become available. Each sample shall consist of four identical, separately packaged subdivisions, each containing at least three times the amount required to perform the laboratory test procedures described in the application to determine compliance with its control specifications for identity and assays:

i. A representative sample or samples of the finished dosage form(s) proposed in the application and employed in the clinical investigations and a representative sample or samples of each new-drug substance, as defined in §310.3(g), from the batch(es) employed in the production of such dosage form(s).

ii. A representative sample or samples of finished market packages of each dosage form of the drug prepared for initial marketing and, if any such sample is not from a commercial-scale production batch, such a sample from a representative commercial-scale production batch; and a representative sample or samples of each new-drug substance as defined in §310.3(g) of the new-drug regulations, from the batch(es) employed in the production of such dosage form(s).

iii. A sample or samples of any reference standard and blank used in the procedures described in the application for assaying each new-drug substance and other assayed components of the finished drug; *Provided, however*, That samples of reference standards recognized in the official U.S. Pharmacopeia or The National Formulary need not be submitted unless requested.

b. Additional samples shall be submitted on request.

c. Each of the samples submitted shall be appropriately packaged and labeled to preserve its characteristics, to identify the material and the quantity in each subdivision of the sample, and to identify each subdivision with name of the applicant and the new-drug application to which it relates.

d. There shall be included a full list of the samples submitted pursuant to Item 9a; a statement of the additional samples that will be submitted as soon as available; and, with respect to each sample submitted, full information with respect to its identity, the origin of any new-drug substance contained therein (including in the case of new-drug substances, a statement whether it was produced on a laboratory, pilot-plant, or full-production scale) and detailed results of all laboratory tests made to determine the identity, strength, quality, and purity of the batch represented by the sample, including assays. Include for any reference standard a complete description of its preparation and the results of all laboratory tests on it. If the test methods used differed from those described in the application, full details of the methods employed

in obtaining the reported results shall be submitted.

e. The requirements of Item 9a may be waived in whole or in part on request of the applicant or otherwise when any such samples are not necessary.

f. If samples of the drug are sent under separate cover, they should be addressed to the attention of the Bureau of Drugs and identified on the outside of the shipping carton with the name of the applicant and the name of the drug as shown on the application.

10. Full reports of preclinical investigations that have been made to show whether or not the drug is safe for use and effective use. a. An application may be refused unless it contains full reports of adequate preclinical tests by all methods reasonably applicable to a determination of the safety and effectiveness of the drug under the conditions of use suggested in the proposed labeling.

b. Detailed reports of the preclinical investigations, including all studies made on laboratory animals, the methods used, and the results obtained, should be clearly set forth. Such information should include identification of the person who conducted each investigation, a statement of where the investigations were conducted, and where the underlying data are available for inspection. The animal studies may not be considered adequate unless they give proper attention to the conditions of use recommended in the proposed labeling for the drug such as, for example, whether the drug is for short- or long-term administration or whether it is to be used in infants, children, pregnant women, or women of child-bearing potential.

c. Detailed reports of any pertinent microbiological and *in vitro* studies.

d. Summarize and provide a list of literature references (if available) to all other preclinical information known to the applicant, whether published or unpublished, that is pertinent to an evaluation of the safety or effectiveness of the drug.

11. List of investigators. a. A complete list of all investigators supplied with the drug including the name and post office address of each investigator and, following each name, the volume and page references to the investigator's report(s) in this application and in any documents incorporated by reference, or the explanation of the omission of any reports.

b. The unexplained omission of any reports of investigations made with the new drug by the applicant, or submitted to him by an investigator, or the unexplained omission of any pertinent reports of investigations or clinical experience received or otherwise obtained by the applicant from published literature or other sources, whether or not it would bias an evaluation of the safety of the drug or its effectiveness in use, may constitute grounds for the refusal or withdrawal of the approval of an application.

12. Full reports of clinical investigations that have been made to show whether or not the drug is safe for use and effective in use. a. An application may be refused unless it contains full reports of adequate tests by all methods reasonably applicable to show whether or not the drug is safe and effective for use as suggested in the labeling.

b. An application may be refused unless it includes substantial evidence consisting of adequate and well-controlled investigations, including clinical investigations, by experts qualified by scientific training and experience to evaluate the effectiveness of the drug involved, on the basis of which it could fairly and responsibly be concluded by such experts that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, recommended, or suggested in the proposed labeling.

c. Reports of all clinical tests sponsored by the applicant or received or otherwise obtained by the applicant should be attached. These reports should include adequate information concerning each subject treated with the drug or employed as a control, including age, sex, conditions treated, dosage, frequency of administration of the drug, results of all relevant clinical observations and laboratory examinations made, full information

concerning any other treatment given previously or concurrently, and a full statement of adverse effects and useful results observed, together with an opinion as to whether such effects or results are attributable to the drug under investigation and a statement of where the underlying data are available for inspection. Ordinarily, the reports of clinical studies will not be regarded as adequate unless they include reports from more than one independent, competent investigator who maintains adequate case histories of an adequate number of subjects; designed to record observations and permit evaluation of any and all discernible effects attributable to the drug in each individual treated and comparable records on any individuals employed as controls. An application for a combination drug may be refused unless there is substantial evidence that each ingredient designated as active makes a contribution to the total effect claimed for the drug combination. Except when the disease for which the drug is being tested occurs with such infrequency in the United States as to make testing impractical, some of the investigations should be performed by competent investigators within the United States.

d. Attach as a separate section a completed Form FD-1639, Drug Experience Report (obtainable, with instructions, on request from the Food and Drug Administration, Department of HEW, 5600 Fishers Lane, Rockville, Maryland 20852), for each adverse experience or, if feasible, for each subject or patient experiencing one or more adverse effects, described in Item 12c, whether or not full information is available. Form FD-1639 should be prepared by the applicant if the adverse experience was not reported in such form by the investigator. The Drug Experience Report should be cross-referenced to any narrative description included in Item 12c. In lieu of a FD Form 1639, a computer-generated report may be submitted if equivalent in all elements of information with the identical enumerated sequence of events and methods of completion; all formats proposed for such use will require initial review and approval by the Food and Drug Administration.

e. All information pertinent to an evaluation of the safety and effectiveness of the drug received or otherwise obtained by the

applicant from any source, including information derived from other investigations or commercial marketing (for example, outside the United States), or reports in the scientific literature, involving the drug that is the subject of the application and related drugs. An adequate summary may be acceptable in lieu of a reprint of a published report which only supports other data submitted. Reprints are not required of reports in designated journals, listed in §310.9 of the new-drug regulations, about related drugs; a bibliography will suffice. Include the evaluation of the safety or effectiveness of the drug that has been made by the applicant's medical department, expert committee, or consultants.

f. If the drug is a combination of previously investigated or marketed drugs, an adequate summary of preexisting information from preclinical and clinical investigation and experience with its components, including all reports received or otherwise obtained by the applicant suggesting side effects, contraindications, and ineffectiveness in use of such components. Such summary should include an adequate bibliography of publications about the components and may incorporate by reference information concerning such components previously submitted by the applicant to the Food and Drug Administration.

g. The complete composition and/or method of manufacture of the new drug used in each submitted report of investigation should be shown to the extent necessary to establish its identity, strength, quality, and purity if it differs from the description in Item 6, 7, or 8 of the application.

13. If this is a supplemental application, full information on each proposed change concerning any statement made in the approved application.

Observe the provisions of §314.8 of the new-drug regulations concerning supplemental applications.

14. [Reserved]

15. The applicant is required to submit an environmental impact analysis report analyzing the environmental impact of the manufacturing process and the ultimate use or consumption of the drug pursuant to §6.1 of this chapter.

Chelsea Laboratories, Inc.

(Applicant)

Nat Getrajdman

Per

(Responsible official or agent)

President

(Indicate authority)

(Warning: A willfully false statement is a criminal offense. U.S.C. Title 18, sec. 1001.)

Note: This application must be signed by the applicant or by an authorized attorney, agent, or official. If the applicant or such authorized representative does not reside or have a place of business within the United States, the application must also furnish the name and post office address of and must be countersigned by an authorized attorney, agent, or official residing or maintaining a place of business within the United States.